Interim Order
193 interim order decisions from Delhi High Court - Orders.
Interim Order Decisions
193 cases | Page 7 of 7
Merck Sharp And Dohme Corp. v.Honour Lab Limited
Merck Sharp And Dohme Corp. filed a suit alleging that Honour Lab Limited was infringing their Indian Patent No. 209816, which covers the molecule SITAGLIPTIN (an API for diabetes treatment). The plaintiffs sought interim relief against the defendant's alleged commercial supply of the patented API.
Sterlite Technologies Limited v.Ztt India Private Limited
The plaintiff sought the discovery of two sets of documents from the defendant: those concerning the manufacturing process of optical fibre and sales data. The court allowed the discovery of sales documents, requiring the defendant to file its audited balance sheet. However, the court denied the immediate necessity of discovering the manufacturing process documents, stating that the initial burden of proof remains with the plaintiff.
Bristol-Myers Squibb Holdings Ireland Unlimited Company v.Bdr Pharmaceuticals International Pvt. Ltd & Anr.
The plaintiffs filed an application seeking action under Contempt of Court because defendant No.1 submitted a tender offering for the sale of Apixaban, despite a prior interim injunction restraining them from dealing in any infringing product covered by Indian Patent No. IN 247381. The court issued show cause notices to the Chairman and Director of defendant No.1 regarding potential contempt proceedings.
Merck Sharp & Dohme Corp. v.Angels Pharma India Private Limited
Merck Sharp & Dohme Corp. filed a suit alleging that Angels Pharma India Private Limited was attempting to manufacture and infringe its Indian Patent No. 209816, which covers the drug SITAGLIPTIN. The court found that the plaintiffs had established a prima facie case and granted interim relief.
Merck Sharp & Dohme Corp And Anr v.Oceanic Pharmachem Pvt. Ltd.
The plaintiffs filed a suit alleging that the defendant was infringing their Indian Patent No. 209816, which covers Sitagliptin and its salts. The plaintiff submitted evidence showing the defendant's online presence advertising and selling infringing Sitagliptin Phosphate API in India. Based on this prima-facie case, the court granted an ad-interim injunction restraining the defendant from dealing in the infringing product.
Merck Sharp & Dohme Corp. v.Everest Organics Limited
Merck Sharp & Dohme Corp. filed a suit seeking permanent injunction against Everest Organics Limited for infringing its registered patent No. 209816, which covers the molecule SITAGLIPTIN. The Plaintiffs alleged that the Defendant was developing and preparing to commercialize an infringing product. Based on the prima facie case presented, the Court granted an ad-interim ex-parte injunction.
Pfizer Inc. v.Everest Pharmaceuticals Ltd.
Pfizer Inc. filed a suit seeking permanent injunction against Everest Pharmaceuticals Ltd. for infringement of Indian Patents Nos. 241773 and 218212, which cover Tofacitinib (XELJANZ(R)). The plaintiffs alleged that defendants were illegally manufacturing and selling generic versions under the brand 'TOFAXEN'.
Merck Sharp & Dohme Corp. v.Achemic Pharmaceuticals (India) Pvt. Ltd.
The plaintiffs, holding patents and licenses for Sitagliptin (under trade names ISTAVEL and ISTAMET), filed a suit alleging that the defendant was manufacturing and selling the drug under the brand name TwoTrack, thereby infringing their patent. The court found that the plaintiffs had made out a prima facie case and granted an ex parte ad interim injunction.
Merck Sharp & Dohme Corp. v.Triveni Interchem Private Limited
The plaintiff, Merck Sharp & Dohme Corp., filed a suit alleging that the defendant, Triveni Interchem Private Limited, was selling and advertising various compositions of Sitagliptin without taking any license. The plaintiff holds a valid patent for Sitagliptin.
All India Patent Officers Welfare Association v.Union Of India & Ors
The All India Patent Officers Welfare Association filed a petition alleging that the Controller General of Patents, Designs and Trademarks (CGPDTM) unlawfully provided access to sensitive, unpublished trademark and patent application data to a private multinational company. The petitioner argued this access lacked necessary checks and balances. The Delhi High Court accepted the petition and directed an investigation into the matter, setting a timeline for the respondents to file their reply.
Novartis Ag v.Natco Pharma Limited
The plaintiffs filed an application seeking to defer or modify the appointment of a scientific expert to determine if the defendant's product, VALSAC, falls within the scope of Claim 1 of their patent (IN 229051). The court accepted the suggestion to appoint an expert from the Roll of Experts and framed a specific question for the appointed Expert Advisor.
Novartis Ag v.Natco Pharma Limited
Novartis filed a suit seeking permanent injunction against Natco Pharma Limited for infringing its patented pharmaceutical composition, Valsartan + Sacubitril (Patent No. 229051). The dispute centered on whether Natco's product, VALSAC, was identical to the claimed invention. The court found prima facie merit in Novartis' contentions and appointed an independent Expert Advisor to determine infringement.
Biogen International Gmbh v.Jayesh Shah
The court passed an order disposing of several applications filed by both parties. The existing interim injunction was confirmed, and the defendant was permitted to sell their existing stock of 'DYFIRA' under specific conditions. This permission required the defendant to furnish a bank guarantee of Rs.30 lacs to secure potential damages.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.